Twist Bioscience Corporation Common Stock (TWST)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Twist Bioscience Corporation Common Stock (TWST)
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Key Insights
Critical company metrics and information
Share Price
$52.70Market Cap
$3.13 BillionTotal Outstanding Shares
59.36 Million SharesTotal Employees
923Dividend
No dividendIPO Date
October 31, 2018SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.twistbioscience.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $6.89 Million |
| Net Cash Flow From Investing Activities | $-3.07 Million |
| Exchange Gains/Losses | $126000.00 |
| Net Cash Flow From Investing Activities, Continuing | $-3.07 Million |
| Net Cash Flow From Financing Activities | $6.89 Million |
| Net Cash Flow From Operating Activities | $-64.09 Million |
| Net Cash Flow, Continuing | $-60.27 Million |
| Net Cash Flow From Operating Activities, Continuing | $-64.09 Million |
| Net Cash Flow | $-60.15 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Basic Average Shares | $58.02 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-208.73 Million |
| Net Income/Loss Attributable To Parent | $-208.73 Million |
| Benefits Costs and Expenses | $521.14 Million |
| Income Tax Expense/Benefit, Current | $560000.00 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Research and Development | $90.85 Million |
| Selling, General, and Administrative Expenses | $218.40 Million |
| Diluted Average Shares | $58.02 Million |
| Income/Loss From Continuing Operations After Tax | $-208.73 Million |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Diluted Earnings Per Share | $3.60 |
| Other Operating Expenses | $44.93 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Operating Expenses | $354.18 Million |
| Net Income/Loss | $-208.73 Million |
| Cost Of Revenue | $179.63 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Revenues | $312.97 Million |
| Operating Income/Loss | $-220.83 Million |
| Income Tax Expense/Benefit | $560000.00 |
| Basic Earnings Per Share | $3.60 |
| Gross Profit | $133.35 Million |
| Income/Loss From Continuing Operations Before Tax | $-208.17 Million |
| Costs And Expenses | $533.80 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $71.01 Million |
| Liabilities | $141.63 Million |
| Equity | $472.69 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Noncurrent Liabilities | $70.63 Million |
| Inventory | $24.08 Million |
| Other Non-current Assets | $165.03 Million |
| Fixed Assets | $102.52 Million |
| Wages | $33.65 Million |
| Other Current Assets | $322.70 Million |
| Accounts Payable | $1.63 Million |
| Noncurrent Assets | $267.55 Million |
| Equity Attributable To Parent | $472.69 Million |
| Assets | $614.32 Million |
| Current Assets | $346.78 Million |
| Other Current Liabilities | $35.73 Million |
| Liabilities And Equity | $614.32 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Related Companies
View additional S&P 500 companies similar to Twist Bioscience Corporation Common Stock (TWST)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.